Pharma's DTC TV spending soars to $3.7B in 2018 by Beth Snyder Bulik Wednesday, January 2, 2019 TV spending on pharma ads continued to rise in 2018, topping $3.73 billion in national TV ad spending, according to data from TV ad tracker iSpot.tv.
Pfizer wins blockbuster patent extension for Lyrica by Eric Sagonowsky Wednesday, November 28, 2018 Pfizer's top drug Lyrica will get another 6 months of protected sales after the FDA granted the drug a pediatric exclusivity extension.
U.K. Supreme Court rejects Pfizer's Lyrica patent appeal by Eric Sagonowsky Wednesday, November 14, 2018 Pfizer has come up short in a long-running patent battle in the U.K. over its blockbuster Lyrica, potentially costing the drugmaker.
Big TV spender Lyrica drops off top 10 in October by Beth Snyder Bulik Monday, November 5, 2018 Is Pfizer’s Lyrica leaving the TV ad game? Facing patent expiration, the stalwart top 10 TV spender dropped its budget to $3.8 million in October.
Pharma TV ad spend beats last year, led by AbbVie and Pfizer by Beth Snyder Bulik Monday, October 15, 2018 With three quarters of pharma TV ad spending down and one to go, national media buys are tracking ahead of 2017, with brands doling out $2.81 billion.
July's big TV spenders Humira, Lyrica drop $25M each by Beth Snyder Bulik Tuesday, August 14, 2018 AbbVie’s Humira, along with Pfizer’s Lyrica and Xeljanz, each spent more than $25 million on TV advertising for July.
AbbVie, Roche, Pfizer cited for 'exploitative' patent strategy by Angus Liu Monday, August 6, 2018 AbbVie has filed for a whopping 247 patent on Humira, an example of how drugmakers try to forestall copycat competition.
AbbVie, Pfizer are becoming an item atop the ad-spend charts by Beth Snyder Bulik Wednesday, May 2, 2018 AbbVie's Humira and Pfizer's Lyrica once again rank No. 1 and No. 2 on our April list for pharma TV ad spending, according to iSpot.tv data.
No need for a megamerger, Pfizer CEO says. Our pipeline's got it by Eric Sagonowsky Tuesday, May 1, 2018 Pfizer CEO Ian Read contends that the company's pipeline is strong enough to fuel growth. In other words, don't look for a "transformative" deal.
No March madness for pharma ad spending as Humira tops list by Beth Snyder Bulik Wednesday, April 11, 2018 AbbVie’s Humira and Pfizer’s Lyrica remained in the top two spots for pharma TV ad spending in March, according to realtime TV ad tracker iSpot.tv.
